Can a blood product fix smallpox vaccine side effects?
NCT ID NCT01374984
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether VIGIV, a blood product with antibodies, helps people who have serious reactions to the smallpox vaccine. It will track 100 patients to see if their skin lesions improve and if their antibody levels change. The goal is to confirm that VIGIV works as a treatment for these rare but severe complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vaccinia Immune Globulin Intravenous (Human) (VIGIV)
- What this could lead to
- If successful, this could confirm that VIGIV effectively treats serious complications from smallpox vaccination, providing a reliable treatment option.
- What could go wrong
- This is an observational post-marketing study, not a controlled trial, so results may be less definitive. The small sample size (100) and lack of a comparison group limit how strongly we can conclude effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLICATION OF SMALLPOX VACCINATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.